AORTIC STENOSIS MARKET ANALYSIS

Aortic Stenosis MarketSize and Trends

The Global Aortic Stenosis Market size is expected to reach US$ 16.77 billion by 2030, from US$ 8.33 billion in 2023, at a CAGR of 10.5% during the forecast period.

Global Aortic Stenosis Market Trends:

• Increasing Adoption of Transcatheter Aortic Valve Replacement (TAVR): TAVR has emerged as a revolutionary treatment for aortic stenosis, especially in high-risk or inoperable patients. The procedure offers several benefits, such as reduced invasiveness, shorter hospital stays, and quicker recovery times. As technology and procedural techniques improve, TAVR has been increasingly adopted as an alternative to surgical aortic valve replacement (SAVR), driving market growth.
• Expanding Indications for TAVR: Initially, TAVR was primarily used for high-risk and inoperable patients. However, with advancements in device design and growing clinical evidence, TAVR has seen an expansion of indications to intermediate-risk and even low-risk patients. The broadening of eligible patient populations has significantly increased the potential market size for TAVR procedures.
• Growing Focus on Minimally Invasive Treatments: Minimally invasive procedures continue to gain traction in the treatment of aortic stenosis. Apart from TAVR, other minimally invasive approaches, such as balloon valvuloplasty, are being explored as potential treatment options. Patients and healthcare providers increasingly prefer these procedures due to their benefits, leading to market expansion.
• Advancements in Aortic Valve Technologies: Continuous advancements in aortic valve technologies have led to the development of new-generation devices that offer improved durability, better outcomes, and enhanced patient safety. Manufacturers are investing in research and development to create innovative devices, fostering competition in the market. For instance, in May 2022, Medtronic, a global leader in medical technology, services, and solution, announced the first patient enrollment in the EXPAND TAVR II Pivotal Trial, the first randomized clinical trial evaluating the self-expanding, supra-annular Evolut TAVR platform in patients with moderate, symptomatic aortic stenosis (AS), a population outside of current guidelines and indications for transcatheter aortic valve replacement (TAVR).